300573 兴齐眼药
已收盘 12-31 15:00:00
资讯
新帖
简况
兴齐眼药:将在会计年度结束后4个月内发布年报
证券之星 · 12-30 16:15
兴齐眼药:将在会计年度结束后4个月内发布年报
兴齐眼药(300573)披露药品生产许可证变更公告,12月29日股价上涨0.45%
证券之星 · 2025-12-29
兴齐眼药(300573)披露药品生产许可证变更公告,12月29日股价上涨0.45%
兴齐眼药:公司目前生产经营情况一切正常
证券之星 · 2025-12-25
兴齐眼药:公司目前生产经营情况一切正常
兴齐眼药(300573)披露关于完成工商变更登记的公告,12月18日股价下跌0.69%
证券之星 · 2025-12-18
兴齐眼药(300573)披露关于完成工商变更登记的公告,12月18日股价下跌0.69%
兴齐眼药(300573)公司公告变更公司住所并修订公司章程,12月17日股价上涨1.88%
证券之星 · 2025-12-17
兴齐眼药(300573)公司公告变更公司住所并修订公司章程,12月17日股价上涨1.88%
兴齐眼药最新公告:SQ-22031滴眼液治疗中至重度干眼Ⅱ期临床试验首例受试者入组
证券之星 · 2025-12-09
兴齐眼药最新公告:SQ-22031滴眼液治疗中至重度干眼Ⅱ期临床试验首例受试者入组
兴齐眼药(300573)披露公司产品继续纳入医保目录,12月08日股价上涨0.16%
证券之星 · 2025-12-08
兴齐眼药(300573)披露公司产品继续纳入医保目录,12月08日股价上涨0.16%
兴齐眼药最新公告:39个产品继续纳入国家医保药品目录
证券之星 · 2025-12-07
兴齐眼药最新公告:39个产品继续纳入国家医保药品目录
兴齐眼药:AI技术有助于推动产品研发
证券之星 · 2025-12-03
兴齐眼药:AI技术有助于推动产品研发
兴齐眼药(300573)披露关于召开2025年第三次临时股东会的通知,12月01日股价上涨1.1%
证券之星 · 2025-12-01
兴齐眼药(300573)披露关于召开2025年第三次临时股东会的通知,12月01日股价上涨1.1%
兴齐眼药:CDE显示“暂停”属审评阶段性状态
证券之星 · 2025-11-27
兴齐眼药:CDE显示“暂停”属审评阶段性状态
兴齐眼药(300573)披露获得药品注册证书,11月25日股价上涨3.36%
证券之星 · 2025-11-25
兴齐眼药(300573)披露获得药品注册证书,11月25日股价上涨3.36%
兴齐眼药最新公告:收到盐酸奥布卡因滴眼液的药品注册证书
证券之星 · 2025-11-24
兴齐眼药最新公告:收到盐酸奥布卡因滴眼液的药品注册证书
兴齐眼药:全渠道营销策略提升产品可及性
证券之星 · 2025-11-14
兴齐眼药:全渠道营销策略提升产品可及性
兴齐眼药:目前公司有四条生产线具备生产0.01%硫酸阿托品滴眼液的GMP资质
证券之星 · 2025-11-13
兴齐眼药:目前公司有四条生产线具备生产0.01%硫酸阿托品滴眼液的GMP资质
兴齐眼药:与海外合作方处于前期沟通阶段
证券之星 · 2025-11-13
兴齐眼药:与海外合作方处于前期沟通阶段
兴齐眼药:公司另外两个浓度阿托品受理号分别为CYHB2401750、CYHB2401751
证券之星 · 2025-11-11
兴齐眼药:公司另外两个浓度阿托品受理号分别为CYHB2401750、CYHB2401751
兴齐眼药:1080582股限售股将于11月7日上市流通
证券日报 · 2025-11-05
兴齐眼药:1080582股限售股将于11月7日上市流通
兴齐眼药:通过学术传播提升品牌知名度
证券之星 · 2025-11-03
兴齐眼药:通过学术传播提升品牌知名度
兴齐眼药(300573)发布向特定对象发行股票募集说明书,10月31日股价下跌3.73%
证券之星 · 2025-10-31
兴齐眼药(300573)发布向特定对象发行股票募集说明书,10月31日股价下跌3.73%
加载更多
公司概况
公司名称:
沈阳兴齐眼药股份有限公司
所属行业:
医药制造业
上市日期:
2016-12-08
主营业务:
沈阳兴齐眼药股份有限公司的主营业务是眼科药物研发、生产、销售。公司的主要产品是眼科药物。公司先后荣获“辽宁省第九届省长质量奖银奖”、“辽宁五一劳动奖状”、“第十四届中国上市公司投资者关系天马奖”、第二十届“全国质量奖”、“国家级绿色工厂”、第十九届中国上市公司董事会金圆桌“优秀董事会”奖、中国上市公司协会“2024年度上市公司董办优秀实践案例”等奖项荣誉,并入选中国上市公司协会2024年上市公司可持续发展优秀实践案例,在眼科处方药物领域中处于优势地位。
发行价格:
5.16
{"stockData":{"symbol":"300573","market":"SZ","secType":"STK","nameCN":"兴齐眼药","latestPrice":70.29,"timestamp":1767164610000,"preClose":69.22,"halted":0,"volume":7744962,"delay":0,"changeRate":0.0155,"floatShares":190000000,"shares":246000000,"eps":2.6223,"marketStatus":"已收盘","change":1.07,"latestTime":"12-31 15:00:00","open":69.3,"high":71.28,"low":68.93,"amount":545000000,"amplitude":0.0339,"askPrice":70.29,"askSize":86,"bidPrice":70.28,"bidSize":82,"shortable":0,"etf":0,"ttmEps":2.6223,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":69.22,"symbolType":"stock","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":76.14,"lowLimit":62.3,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":246429527,"isCdr":false,"pbRate":9.18,"roa":"--","peRate":26.804713,"roe":"32.91%","epsLYR":1.94,"committee":0.344992,"marketValue":17322000000,"turnoverRate":0.0409,"status":0,"floatMarketCap":13322000000},"requestUrl":"/m/hq/s/300573","defaultTab":"news","newsList":[{"id":"2595670177","title":"兴齐眼药:将在会计年度结束后4个月内发布年报","url":"https://stock-news.laohu8.com/highlight/detail?id=2595670177","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595670177?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:15","pubTimestamp":1767082514,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药(300573)12月30日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵司什么时候发布年报?兴齐眼药回复:尊敬的投资者您好,根据相关规定,公司将在每个会计年度结束后的4个月内发布年报。具体时间请以巨潮资讯网公布的预约披露时间为准,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000023261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2595573515","title":"兴齐眼药(300573)披露药品生产许可证变更公告,12月29日股价上涨0.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595573515","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595573515?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:22","pubTimestamp":1767018139,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘,兴齐眼药报收于68.87元,较前一交易日上涨0.45%,最新总市值为169.72亿元。该股当日开盘68.48元,最高69.7元,最低68.38元,成交额达3.46亿元,换手率为2.64%。公司近日发布公告称,沈阳兴齐眼药股份有限公司取得辽宁省药品监督管理局下发的《药品生产许可证》,主要变更为住所地址。生产地址和生产范围未发生变化。本次变更不会对公司生产经营产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900037878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2594234701","title":"兴齐眼药:公司目前生产经营情况一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2594234701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594234701?lang=zh_cn&edition=full","pubTime":"2025-12-25 20:50","pubTimestamp":1766667011,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药12月25日在投资者关系平台上答复投资者关心的问题。公司产品是否滞销?公司一直致力于通过提升经营业绩来为股东创造价值,并依据发展战略及经营目标,加强精细化管理,持续控制运营成本,优化公司费用率,提升公司盈利能力。股票回购需根据公司资金安排并结合实际经营情况经决策后方可确定,未来如有回购相关计划,公司将依规进行公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500033309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2592790481","title":"兴齐眼药(300573)披露关于完成工商变更登记的公告,12月18日股价下跌0.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592790481","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592790481?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:13","pubTimestamp":1766067207,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘,兴齐眼药报收于67.67元,较前一交易日下跌0.69%,最新总市值为166.76亿元。该股当日开盘67.71元,最高68.8元,最低67.53元,成交额达2.31亿元,换手率为1.79%。公司近日发布公告称,沈阳兴齐眼药股份有限公司已完成工商变更登记,并取得沈阳市浑南区市场监督管理局颁发的《营业执照》。公司住所变更为辽宁省沈阳市浑南区新运河路25号。本次变更事项已通过董事会及股东会审议,具体内容以工商登记为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800038373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2592913046","title":"兴齐眼药(300573)公司公告变更公司住所并修订公司章程,12月17日股价上涨1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592913046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592913046?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:11","pubTimestamp":1765980711,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘,兴齐眼药报收于68.14元,较前一交易日上涨1.88%,最新总市值为167.92亿元。公司近日发布公告称,于2025年12月17日召开2025年第三次临时股东会,会议以现场投票与网络投票相结合的方式进行。出席会议的股东及股东代表共361人,代表股份82,243,039股,占公司有表决权股份总数的33.3739%。会议审议通过了《关于变更公司住所并修订公司章程的议案》,该议案获得有效表决权股份总数的99.3507%同意,已达到特别决议通过条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2590435823","title":"兴齐眼药最新公告:SQ-22031滴眼液治疗中至重度干眼Ⅱ期临床试验首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2590435823","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590435823?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:50","pubTimestamp":1765281023,"startTime":"0","endTime":"0","summary":"兴齐眼药公告称,公司研发的SQ-22031滴眼液已完成“一项评估SQ-22031滴眼液治疗中至重度干眼的有效性和安全性的多中心、随机、双盲、安慰剂对照的Ⅱ期临床研究”首例受试者入组,正式进入Ⅱ期临床试验。该药物为治疗用生物制品1类,适应症为干眼。SQ-22031滴眼液能促进感觉神经元和交感神经元生长和存活,恢复受损神经元功能,使患者角膜损伤迅速愈合,改善角膜知觉和泪液生成量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900034673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2589339879","title":"兴齐眼药(300573)披露公司产品继续纳入医保目录,12月08日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589339879","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589339879?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:48","pubTimestamp":1765187299,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘,兴齐眼药报收于73.09元,较前一交易日上涨0.16%,最新总市值为180.12亿元。该股当日开盘73.19元,最高74.18元,最低72.97元,成交额达4.49亿元,换手率为3.23%。近日,国家医保局等部门发布《国家基本医疗保险、生育保险和工伤保险药品目录》,沈阳兴齐眼药股份有限公司共有39个产品继续纳入国家医保药品目录,其中甲类8个,乙类31个,无产品退出。新版目录自2026年1月1日起执行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800022072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2589507879","title":"兴齐眼药最新公告:39个产品继续纳入国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589507879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589507879?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:19","pubTimestamp":1765095575,"startTime":"0","endTime":"0","summary":"兴齐眼药(300573.SZ)公告称,公司共有39个产品继续纳入国家医保药品目录,包括甲类8个,乙类31个。环孢素滴眼液(Ⅱ)、复方电解质眼内冲洗液、玻璃酸钠滴眼液等产品继续纳入《国家医保目录》,没有产品退出。新版《国家医保药品目录》将于2026年1月1日起正式执行,但短期内不会对公司本报告期的经营业绩构成重大影响。药品未来销售情况受医药行业政策变动、市场环境变化等影响,具有不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700003971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2588046710","title":"兴齐眼药:AI技术有助于推动产品研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588046710?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:51","pubTimestamp":1764766287,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药(300573)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问:目前人工智能的高速发展对公司产品的研发有什么帮助?公司目前是否充分通过人工智能来帮助进行药物研发,谢谢兴齐眼药回复:尊敬的投资者您好,AI技术有助于推动产品的研发。公司将持续密切关注人工智能等前沿技术发展方向,通过AI赋能科技创新。谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300037191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2588775393","title":"兴齐眼药(300573)披露关于召开2025年第三次临时股东会的通知,12月01日股价上涨1.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588775393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588775393?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:19","pubTimestamp":1764598781,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘,兴齐眼药报收于72.68元,较前一交易日上涨1.1%,最新总市值为179.1亿元。该股当日开盘72.0元,最高72.68元,最低71.2元,成交额达4.08亿元,换手率为2.99%。公司近日发布公告称,沈阳兴齐眼药股份有限公司将于2025年12月17日召开2025年第三次临时股东会,会议由董事会召集,现场会议时间为当日14:30,网络投票时间为当日9:15至15:00。股权登记日为2025年12月11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100036599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","BK0239","300573"],"gpt_icon":0},{"id":"2586210918","title":"兴齐眼药:CDE显示“暂停”属审评阶段性状态","url":"https://stock-news.laohu8.com/highlight/detail?id=2586210918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586210918?lang=zh_cn&edition=full","pubTime":"2025-11-27 16:03","pubTimestamp":1764230600,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药(300573)11月27日在投资者关系平台上答复投资者关心的问题。投资者提问:公司硫酸阿托品药剂在CDE官网显示,评审状态为暂停。请问该药品暂停评审意味着该药品审批被拒从而无法上市了吗?兴齐眼药回复:尊敬的投资者您好,国家药品监督管理局药品审评中心(CDE)显示的“暂停”状态属于药品注册审评过程中的阶段性状态,公司项目进展请关注国家药品监督管理局网站及公司后续公告,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700018339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2586542616","title":"兴齐眼药(300573)披露获得药品注册证书,11月25日股价上涨3.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586542616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586542616?lang=zh_cn&edition=full","pubTime":"2025-11-25 17:47","pubTimestamp":1764064076,"startTime":"0","endTime":"0","summary":"截至2025年11月25日收盘,兴齐眼药报收于71.44元,较前一交易日上涨3.36%,最新总市值为176.05亿元。该股当日开盘69.32元,最高71.88元,最低69.32元,成交额达5.8亿元,换手率为4.3%。公司近日发布公告称,沈阳兴齐眼药股份有限公司收到国家药品监督管理局核准签发的盐酸奥布卡因滴眼液《药品注册证书》。产品为不含抑菌剂单剂量制剂,上市许可持有人和生产企业均为公司自身,药品批准文号有效期至2030年11月17日。目前该品种已有仿制药在国内获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500026928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2585693684","title":"兴齐眼药最新公告:收到盐酸奥布卡因滴眼液的药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2585693684","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585693684?lang=zh_cn&edition=full","pubTime":"2025-11-24 19:30","pubTimestamp":1763983825,"startTime":"0","endTime":"0","summary":"兴齐眼药(300573.SZ)公告称,公司收到国家药品监督管理局核准签发的盐酸奥布卡因滴眼液《药品注册证书》。该药品为不含抑菌剂单剂量产品,适应症为眼科领域内的表面麻醉。原研药品已进口中国,国内已有同品种仿制药获批上市。药品注册标准编号为YBH28692025,上市许可持有人为沈阳兴齐眼药股份有限公司,批准文号为国药准字H20255980,有效期至2030年11月17日。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400029246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2583573532","title":"兴齐眼药:全渠道营销策略提升产品可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=2583573532","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583573532?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:15","pubTimestamp":1763108114,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药11月14日在投资者关系平台上答复投资者关心的问题。通过持续推进学术推广、普及近视防控科普教育及完善药事服务体系,不断提升产品可及性与患者用药体验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400024662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2583554895","title":"兴齐眼药:目前公司有四条生产线具备生产0.01%硫酸阿托品滴眼液的GMP资质","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583554895?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:12","pubTimestamp":1763021538,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药(300573)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:公司有四条生产线具备生产 0.01%硫酸阿托品滴眼液的GMP 资质,现阶段可以满足市场需求。请问截止目前公司还是这四条产线吗?产线够用吗?兴齐眼药回复:尊敬的投资者您好,目前公司有四条生产线具备生产0.01%硫酸阿托品滴眼液的GMP资质,现阶段产能可满足市场需求。未来,公司将根据市场需求变化,做产能调整和布局,感谢您的关注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300026160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0177","BK0239"],"gpt_icon":0},{"id":"2583554813","title":"兴齐眼药:与海外合作方处于前期沟通阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554813","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583554813?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:12","pubTimestamp":1763021533,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药(300573)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的公司领导 这次双十一销量怎么样?有没有出海BD考虑?兴齐眼药回复:尊敬的投资者您好,目前我司与海外合作方的合作处于前期沟通阶段,后续达到信息披露节点时,我们将严格按照相关规定及时履行信息披露义务。关于销售的具体情况,请您关注公司定期报告。谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300026151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300573","BK0239","BK0177"],"gpt_icon":0},{"id":"2582359290","title":"兴齐眼药:公司另外两个浓度阿托品受理号分别为CYHB2401750、CYHB2401751","url":"https://stock-news.laohu8.com/highlight/detail?id=2582359290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582359290?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:48","pubTimestamp":1762850907,"startTime":"0","endTime":"0","summary":"证券之星消息,兴齐眼药(300573)11月11日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,贵公司0.02%、0.04%阿托品的受理号是多少?上次回复正在评审中。请问评审过程中药监局是要求贵公司补充材料?一旦通过评审贵公司是否会第一时间披露该消息?谢谢!兴齐眼药回复:尊敬的投资者您好,公司另外两个浓度阿托品受理号分别为CYHB2401750、CYHB2401751。公司会在获得药品注册批件时及时履行信息披露义务。谢谢。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100025985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0},{"id":"2581212167","title":"兴齐眼药:1080582股限售股将于11月7日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2581212167","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581212167?lang=zh_cn&edition=full","pubTime":"2025-11-05 19:39","pubTimestamp":1762342740,"startTime":"0","endTime":"0","summary":"证券日报网讯 11月5日晚间,兴齐眼药发布关于2021年限制性股票激励计划第四个归属期归属结果暨股份上市公告称,公司本次第二类限制性股票的归属数量为1,080,582股,占归属前公司总股本的0.44%,归属人数为77人。本次第二类限制性股票的归属日为2025年11月7日。本次第二类限制性股票上市流通日期为2025年11月7日,本次归属的限制性股票不设限售期。(文章来源:证券日报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkazr4241925.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwkazr4241925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0177","300573","BK0239"],"gpt_icon":0},{"id":"2580267536","title":"兴齐眼药:通过学术传播提升品牌知名度","url":"https://stock-news.laohu8.com/highlight/detail?id=2580267536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580267536?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:39","pubTimestamp":1762159168,"startTime":"0","endTime":"0","summary":"在未来竞争中,形成选择优势和价格溢价的龙头地位兴齐眼药回复:尊敬的投资者您好,硫酸阿托品滴眼液作为一款处方药物,产品推广需遵守国家药品广告管理的相关规定。公司一直高度重视品牌建设,在积极开展全渠道营销不断提升产品可及性与患者用药体验的同时,通过参与医药专业协会组织的眼健康学术专题,持续传播学术知识与品牌声音,不断提升公司品牌知名度,为业务的稳健增长筑牢坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300021818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300573","BK0177"],"gpt_icon":0},{"id":"2579459686","title":"兴齐眼药(300573)发布向特定对象发行股票募集说明书,10月31日股价下跌3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579459686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579459686?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:18","pubTimestamp":1761902309,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘,兴齐眼药报收于80.21元,较前一交易日下跌3.73%,最新总市值为196.79亿元。近日,沈阳兴齐眼药股份有限公司披露了《向特定对象发行股票募集说明书(申报稿)》。公告显示,公司拟向特定对象发行股票,募集资金总额不超过78,978.56万元,用于研发中心建设项目及补充流动资金。发行价格不低于定价基准日前20个交易日公司股票交易均价的80%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100035713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0177","300573"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767290065947,"stockEarnings":[{"period":"1week","weight":0.0224},{"period":"1month","weight":-0.0329},{"period":"3month","weight":0.0694},{"period":"6month","weight":0.3589},{"period":"1year","weight":0.4434},{"period":"ytd","weight":0.4434}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"沈阳兴齐眼药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54149人(较上一季度增加16.85%)","perCapita":"3500股","listingDate":"2016-12-08","address":"辽宁省沈阳市浑南区中国(辽宁)自由贸易试验区沈阳片区新运河路25号","registeredCapital":"24642万元","survey":" 沈阳兴齐眼药股份有限公司的主营业务是眼科药物研发、生产、销售。公司的主要产品是眼科药物。公司先后荣获“辽宁省第九届省长质量奖银奖”、“辽宁五一劳动奖状”、“第十四届中国上市公司投资者关系天马奖”、第二十届“全国质量奖”、“国家级绿色工厂”、第十九届中国上市公司董事会金圆桌“优秀董事会”奖、中国上市公司协会“2024年度上市公司董办优秀实践案例”等奖项荣誉,并入选中国上市公司协会2024年上市公司可持续发展优秀实践案例,在眼科处方药物领域中处于优势地位。","listedPrice":5.16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兴齐眼药,300573,兴齐眼药股票,兴齐眼药股票老虎,兴齐眼药股票老虎国际,兴齐眼药行情,兴齐眼药股票行情,兴齐眼药股价,兴齐眼药股市,兴齐眼药股票价格,兴齐眼药股票交易,兴齐眼药股票购买,兴齐眼药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兴齐眼药(300573)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兴齐眼药(300573)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}